Discounted Cash Flow (DCF) Analysis Levered

Nanobiotix S.A. (NANO.PA)

3.58 €

+0.02 (+0.56%)
All numbers are in Millions, Currency in USD
Stock DCF: 0.70 | 3.58 | overvalue

Free Cash Flow

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue 0.250.120.070.050.0100000
Revenue (%)
Operating Cash Flow -21.03-25.99-41.17-27.54-29.87-4.41-2.19-1.08-0.54-0.27
Operating Cash Flow (%)
Capital Expenditure --0.51-1.44-0.11-0.23-0.06-0.03-0.02-0.01-0
Capital Expenditure (%)
Free Cash Flow -21.03-26.49-42.61-27.64-30.11-4.47-2.22-1.10-0.54-0.27

Weighted Average Cost Of Capital

Share price $ 3.58
Beta 1.885
Diluted Shares Outstanding 107.49
Cost of Debt
Tax Rate -0.01
After-tax Cost of Debt 5.00%
Risk-Free Rate
Market Risk Premium
Cost of Equity 12.273
Total Debt -
Total Equity 384.80
Total Capital 384.80
Debt Weighting 0.00
Equity Weighting 100.00
Wacc

Build Up Free Cash Flow

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue 0.250.120.070.050.0100000
Operating Cash Flow -21.03-25.99-41.17-27.54-29.87-4.41-2.19-1.08-0.54-0.27
Capital Expenditure --0.51-1.44-0.11-0.23-0.06-0.03-0.02-0.01-0
Free Cash Flow -21.03-26.49-42.61-27.64-30.11-4.47-2.22-1.10-0.54-0.27
WACC
PV LFCF -3.98-1.76-0.78-0.34-0.15
SUM PV LFCF -7.01

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 12.27
Free cash flow (t + 1) -0.28
Terminal Value -2.68
Present Value of Terminal Value -1.50

Intrinsic Value

Enterprise Value -8.51
Net Debt -83.92
Equity Value 75.41
Shares Outstanding 107.49
Equity Value Per Share 0.70